Michelle Werner

Michelle Werner joined Flagship Pioneering in 2022 as CEO Partner and CEO of Alltrna. Michelle brings more than two decades of pharmaceutical leadership spanning both Commercial and Research and Development responsibilities. She most recently served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology where she was responsible for delivering the disease area strategies across multiple tumors and led business development efforts to strengthen the long-term portfolio value for the franchise. Prior to her time at Novartis, Michelle was a senior leader at AstraZeneca where she held multiple positions during her 5-year tenure. At AstraZeneca she was critical in launching multiple indications worldwide for CALQUENCE and was responsible for developing the mid- and long-term strategy in Hematology. As Head of US Oncology, she led the business through dramatic growth in both team and revenue through more than eight product launches. She also served as Country President for the Nordics and Baltics where she was an elected Board Member to Sweden’s pharmaceutical industry association.

Michelle previously spent ten years with Bristol-Myers Squibb including roles in Sales, Marketing, and Market Access in both the US and the UK, and above market in Europe and Global almost exclusively in Oncology. Michelle started her professional career in R&D, working hands-on with patients at the Oncology Clinical Trials Unit at Harvard Medical School before moving into industry in clinical operations.

She received a B.A. in Biology and Anthropology from the University of Pennsylvania and an MBA from the London Business School. She completed an Executive Education program for Women on Boards at Harvard Business School and is a Board member for the non-profit organization Rare Disease Renegades.